Feb 11, 2025 · Rimcure 3 Fdc 150 mg/75 mg/400 mg Tablet is used to treat tuberculosis, an infectious disease that mainly affects the lungs but can affect other parts of the body as well. It kills as well as stops the growth of infection causing bacteria and helps in treating the infection.

The evaluated doses of empagliflozin/linagliptin/metformin XR FDC tablets were bioequivalent to the corresponding free combinations. Based on these two bioequivalence studies and existing phase 3 data, the FDA has recently approved this triple …

Fixed-dose combination (FDC) drugs were initially developed to target a single disease, as with antiretroviral FDCs [[indication (medicine)|indicated for treatment of AIDS. FDC drugs may also target multiple disorders or diseases, which may be related to, or comorbid with (occurring alongside) each other.

Examples of FDC layered tablets incorporating the antidiabetic drug glimepiride and metformin are Glimser-1 ® (Alembic), Glycomett ®-GP 0.5 (USV), GLIMKAR-M2-FORTE (Care Formulation Labs), GLYSAP-M1 (Elxir), and GLITIP-2 Tablets (IVA Healthcare).

Jun 27, 2024 · The FDC tablet doravirine (DOR)/3TC/TDF is approved by the FDA for children and adolescents weighing ≥35 kg who are antiretroviral (ARV) naive or virologically suppressed on a stable ARV regimen (see the Doravirine section).

Jan 7, 2025 · The tablets should be given as a single dose, preferably on an empty stomach, at least 30 min before breakfast to ensure a high peak serum concentration. Tablets are recommended in the initial intensive phase of the short course treatment of tuberculosis.

Rimcure 3 FDC is a prescription medication. It is a tablet that is used in the treatment of tuberculosis. It is a fixed-dose combination of three medications, namely Rifampicin, Isoniazid, and Pyrazi

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement.

We evaluated the bioequivalence of 2 doses of an FDC of extended-release metformin (metformin XR), empagliflozin, a sodium-glucose co-transporter 2 inhibitor, and linagliptin, a dipeptidyl pepti-dase-4 inhibitor, versus corresponding free tablet combinations.

A previous study revealed that a three-drug FDC (3-FDC) regimen resulted in fewer drug-related adverse events than separate formulations (SFs) of anti-TB drugs did; however, the study method was self-administered treatment and was did not implement the DOTS 10.